Leerink Partnrs Issues Negative Estimate for REGN Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) - Stock analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Regeneron Pharmaceuticals in a report issued on Monday, July 7th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will earn $8.33 per share for the quarter, down from their previous estimate of $8.77. The consensus estimate for Regeneron Pharmaceuticals' current full-year earnings is $35.92 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals' Q4 2025 earnings at $8.44 EPS, FY2025 earnings at $29.95 EPS and FY2026 earnings at $31.25 EPS.

REGN has been the topic of a number of other research reports. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Robert W. Baird reduced their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a report on Friday, April 25th. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $700.00 to $580.00 in a research report on Friday, May 30th. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. Finally, The Goldman Sachs Group lowered their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $823.54.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded up $7.98 during midday trading on Tuesday, hitting $567.74. The company's stock had a trading volume of 844,505 shares, compared to its average volume of 915,680. The stock has a fifty day moving average price of $545.22 and a 200 day moving average price of $620.50. The firm has a market capitalization of $61.29 billion, a price-to-earnings ratio of 14.45, a P/E/G ratio of 2.08 and a beta of 0.33. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $1,211.20. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company's revenue was down 3.7% compared to the same quarter last year. During the same period last year, the business posted $9.55 EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Brighton Jones LLC boosted its stake in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after purchasing an additional 686 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Regeneron Pharmaceuticals by 107.7% during the fourth quarter. Jones Financial Companies Lllp now owns 812 shares of the biopharmaceutical company's stock valued at $578,000 after purchasing an additional 421 shares in the last quarter. Proficio Capital Partners LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 30.5% during the fourth quarter. Proficio Capital Partners LLC now owns 308 shares of the biopharmaceutical company's stock valued at $219,000 after purchasing an additional 72 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $65,180,000. Finally, Larson Financial Group LLC increased its holdings in Regeneron Pharmaceuticals by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 81 shares of the biopharmaceutical company's stock worth $58,000 after buying an additional 31 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.62%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.